Q1 2026 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2026-05-15 · accession 0001193125-26-226588
$1.16B
Reported value
5
Positions
2026-03-31
Period end
The Brief · Flagship Pioneering, LLC · Q1 2026
AI · grounded in 13F
Flagship Pioneering, LLC established a new position in GENB with an investment of $783.4M. This addition represents the fund's only change to its portfolio this period. The fund now manages 5 positions with total assets under management of $1.16B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 370920100 | GENB | GENERATE BIOMEDICINES INC | $783.4M | 67.4% | 62,673,117 | Common | SHARED |
| 60770K107 | MRNA | MODERNA INC | $235.3M | 20.3% | 4,632,149 | Common | SHARED |
| 799566104 | SANA | SANA BIOTECHNOLOGY INC | $72.0M | 6.20% | 25,001,856 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $60.6M | 5.22% | 12,674,120 | Common | SHARED |
| 81750R201 | MCRB | SERES THERAPEUTICS INC | $10.3M | 0.88% | 1,155,850 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.